Tomoo Okamura
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Long-term safety and effectiveness of linagliptin by baseline body mass index in Japanese patients with type 2 diabetes: a 3-year post-marketing surveillance study.
Journal: Expert opinion on drug safety
Published: April 14, 2022
Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type 2 diabetes: a rapid evidence assessment and narrative synthesis.
Journal: Expert opinion on drug safety
Published: March 12, 2021
Long-term safety and effectiveness of linagliptin as add-on therapy in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance.
Journal: Expert opinion on drug safety
Published: December 03, 2020
Cost-Effectiveness Analysis of Linagliptin in Japan Based on Results from the Asian Subpopulation in the CARMELINA® Trial.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: May 19, 2020
Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA® trial.
Journal: Diabetology international
Published: February 12, 2020
Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes and Renal Dysfunction: a Post-Marketing Surveillance Study.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: November 13, 2019
Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes Mellitus: A 3-Year Post-Marketing Surveillance Study.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: August 28, 2019
Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial.
Journal: Diabetology international
Published: August 09, 2019
Cost-effectiveness Analysis of Empagliflozin in Japan Based on Results From the Asian subpopulation in the EMPA-REG OUTCOME Trial.
Journal: Clinical therapeutics
Published: November 16, 2018
Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME® trial.
Journal: Journal of diabetes investigation
Published: July 13, 2018
Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials.
Journal: Journal of diabetes investigation
Published: May 13, 2018
Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: January 08, 2018
Last Updated: 09/26/2026